Loading...

Fund Overview

Fund Size

Fund Size

₹214 Cr

Expense Ratio

Expense Ratio

0.47%

ISIN

ISIN

INF00XX01BO9

Minimum SIP

Minimum SIP

₹1,000

Exit Load

Exit Load

1.00%

Inception Date

Inception Date

11 Nov 2021

About this fund

ITI Pharma and Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by ITI Mutual Fund. This fund has been in existence for 3 years, 5 months and 8 days, having been launched on 11-Nov-21.
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹16.92, Assets Under Management (AUM) of 213.77 Crores, and an expense ratio of 0.47%.
  • ITI Pharma and Healthcare Fund Direct Growth has given a CAGR return of 16.54% since inception.
  • The fund's asset allocation comprises around 97.95% in equities, 0.00% in debts, and 2.05% in cash & cash equivalents.
  • You can start investing in ITI Pharma and Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+18.55%

+17.55% (Cat Avg.)

3 Years

+20.04%

+18.10% (Cat Avg.)

Since Inception

+16.54%

(Cat Avg.)

Portfolio Summaryas of 31st March 2025

Equity209.4 Cr97.95%
Others4.37 Cr2.05%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Sun Pharmaceuticals Industries LtdEquity34.67 Cr16.22%
Divi's Laboratories LtdEquity12.74 Cr5.96%
Lupin LtdEquity12.35 Cr5.78%
Suven Pharmaceuticals LtdEquity11.52 Cr5.39%
Apollo Hospitals Enterprise LtdEquity11.03 Cr5.16%
Max Healthcare Institute Ltd Ordinary SharesEquity10.83 Cr5.07%
Torrent Pharmaceuticals LtdEquity8.79 Cr4.11%
Aurobindo Pharma LtdEquity7.71 Cr3.61%
Mankind Pharma LtdEquity6.6 Cr3.09%
Alkem Laboratories LtdEquity6.08 Cr2.84%
Aster DM Healthcare Ltd Ordinary SharesEquity6.02 Cr2.81%
Abbott India LtdEquity5.19 Cr2.43%
Neuland Laboratories LimitedEquity4.87 Cr2.28%
Net Receivables / (Payables)Cash4.37 Cr2.05%
Granules India LtdEquity4.26 Cr1.99%
Dr Reddy's Laboratories LtdEquity4.08 Cr1.91%
Wockhardt LtdEquity4.05 Cr1.90%
HealthCare Global Enterprises LtdEquity3.68 Cr1.72%
Supriya Lifescience LtdEquity3.65 Cr1.71%
Fortis Healthcare LtdEquity3.34 Cr1.56%
Sumitomo Chemical India Ltd Ordinary SharesEquity3.24 Cr1.52%
FDC LtdEquity3.07 Cr1.44%
GlaxoSmithKline Pharmaceuticals LtdEquity2.97 Cr1.39%
Rainbow Childrens Medicare LtdEquity2.82 Cr1.32%
Orchid Pharma LtdEquity2.81 Cr1.32%
Caplin Point Laboratories LtdEquity2.65 Cr1.24%
J.B. Chemicals & Pharmaceuticals LtdEquity2.63 Cr1.23%
Gland Pharma LtdEquity2.62 Cr1.22%
Emcure Pharmaceuticals LtdEquity2.5 Cr1.17%
Sai Life Sciences LtdEquity2.26 Cr1.06%
Vijaya Diagnostic Centre LtdEquity2.25 Cr1.05%
Cipla LtdEquity2.22 Cr1.04%
OneSource Specialty Pharma LtdEquity2.19 Cr1.03%
Shilpa Medicare LtdEquity2.19 Cr1.02%
SRF LtdEquity2.1 Cr0.98%
UPL LtdEquity2.04 Cr0.95%
Linde India LtdEquity1.96 Cr0.92%
Sequent Scientific LtdEquity1.95 Cr0.91%
Strides Pharma Science LtdEquity1.84 Cr0.86%
Laurus Labs LtdEquity1.59 Cr0.74%

Allocation By Market Cap (Equity)

Large Cap Stocks

29.24%

Mid Cap Stocks

33.78%

Small Cap Stocks

31.63%

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare195.18 Cr91.30%
Basic Materials7.25 Cr3.39%
Industrials2.1 Cr0.98%

Risk & Performance Ratios

Standard Deviation

This fund

16.41%

Cat. avg.

16.77%

Lower the better

Sharpe Ratio

This fund

0.83

Cat. avg.

0.75

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

1.30

Higher the better

Fund Managers

Dhimant Shah

Dhimant Shah

Since December 2022

Rohan Korde

Rohan Korde

Since November 2021

Additional Scheme Detailsas of 31st March 2025

ISIN
INF00XX01BO9
Expense Ratio
0.47%
Exit Load
1.00%
Fund Size
₹214 Cr
Age
3 years 5 months
Lumpsum Minimum
₹5,000
Fund Status
Open Ended Investment Company
Benchmark
Nifty Healthcare TR INR

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

iconCapital Gains Taxation:

iconDividend Taxation:

info icon

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund nameExpense RatioExit LoadFund size
1Y
Bajaj Finserv Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹307.40 Cr-
Bajaj Finserv Healthcare Fund Direct Growth

Very High Risk

0.6%1.0%₹307.40 Cr-
PGIM India Healthcare Fund Direct Growth

Very High Risk

0.7%0.0%₹104.18 Cr-
PGIM India Healthcare Fund Regular Growth

Very High Risk

2.4%0.0%₹104.18 Cr-
WhiteOak Capital Pharma and Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹303.62 Cr26.8%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth

Very High Risk

0.6%1.0%₹303.62 Cr29.0%
DSP Nifty Healthcare ETF Regular Growth

Very High Risk

0.2%-₹9.77 Cr15.8%
Kotak Healthcare Fund Direct Growth

Very High Risk

0.8%0.0%₹411.54 Cr16.3%
Kotak Healthcare Fund Regular Growth

Very High Risk

2.4%0.0%₹411.54 Cr14.4%
HDFC Pharma and Healthcare Fund Regular Growth

Very High Risk

2.1%1.0%₹1634.08 Cr27.7%

About the AMC

ITI Mutual Fund

ITI Mutual Fund

Total AUM

₹7,941 Cr

Address

Mumbai, 400013

Other Funds by ITI Mutual Fund

Fund nameExpense RatioExit LoadFund size
1Y
ITI Focused Equity Fund Direct Growth

Very High Risk

0.7%1.0%₹478.53 Cr12.4%
ITI Liquid Fund Direct Growth

Low to Moderate Risk

0.1%0.0%₹48.22 Cr7.2%
ITI Ultra Short Duration Fund Direct Growth

Low to Moderate Risk

0.2%0.0%₹180.28 Cr7.6%
ITI Multi Cap Fund Direct Growth

Very High Risk

0.3%1.0%₹1116.36 Cr3.0%
ITI Value Fund Direct Growth

Very High Risk

0.6%1.0%₹297.69 Cr2.4%
ITI Conservative Hybrid Fund Direct Growth

Moderate Risk

0.2%0.0%₹14.80 Cr8.9%
ITI Dynamic Bond Fund Direct Growth

Moderate Risk

0.1%0.0%₹39.64 Cr11.8%
ITI Balanced Advantage Fund Direct Growth

Very High Risk

0.6%1.0%₹382.77 Cr6.8%
ITI Small Cap Fund Direct Growth

Very High Risk

0.6%1.0%₹2219.20 Cr11.1%
ITI Large Cap Fund Direct Growth

Very High Risk

0.6%1.0%₹472.57 Cr3.9%
ITI Banking & PSU Debt Fund Direct Growth

Moderate Risk

0.1%0.0%₹34.80 Cr9.2%
ITI Banking and Financial Services Fund Direct Growth

Very High Risk

0.6%1.0%₹287.76 Cr17.0%
ITI Arbitrage Fund Direct Growth

Low Risk

0.2%0.0%₹47.67 Cr7.8%
ITI Overnight Fund Direct Growth

Low Risk

0.1%0.0%₹21.96 Cr6.4%
ITI Mid Cap Fund Direct Growth

Very High Risk

0.2%1.0%₹1091.64 Cr7.1%
ITI Long Term Equity Fund Direct Growth

Very High Risk

0.6%0.0%₹377.68 Cr7.7%
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹213.77 Cr18.5%
ITI Flexi Cap Fund Direct Growth

Very High Risk

0.2%1.0%₹1031.77 Cr8.2%

Risk Level

Your principal amount will be at Very High Risk

Very High Risk

Take control of your wealth

Track and Analyse all your investments with Wealth Monitor

qr

Rated ★ 4.3+ on

playstoreappstore

Still got questions?
We're here to help.

The NAV of ITI Pharma and Healthcare Fund Direct Growth, as of 17-Apr-2025, is ₹16.92.
The fund has generated 18.55% over the last 1 year and 20.04% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.
The fund's allocation of assets is distributed as 97.95% in equities, 0.00% in bonds, and 2.05% in cash and cash equivalents.
The fund managers responsible for ITI Pharma and Healthcare Fund Direct Growth are:-
  1. Dhimant Shah
  2. Rohan Korde

Fund Overview

Fund Size

Fund Size

₹214 Cr

Expense Ratio

Expense Ratio

0.47%

ISIN

ISIN

INF00XX01BO9

Minimum SIP

Minimum SIP

₹1,000

Exit Load

Exit Load

1.00%

Inception Date

Inception Date

11 Nov 2021

Risk Level

Your principal amount will be at Very High Risk

Very High Risk

About this fund

ITI Pharma and Healthcare Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by ITI Mutual Fund. This fund has been in existence for 3 years, 5 months and 8 days, having been launched on 11-Nov-21.
As of 17-Apr-25, it has a Net Asset Value (NAV) of ₹16.92, Assets Under Management (AUM) of 213.77 Crores, and an expense ratio of 0.47%.
  • ITI Pharma and Healthcare Fund Direct Growth has given a CAGR return of 16.54% since inception.
  • The fund's asset allocation comprises around 97.95% in equities, 0.00% in debts, and 2.05% in cash & cash equivalents.
  • You can start investing in ITI Pharma and Healthcare Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+18.55%

+17.55% (Cat Avg.)

3 Years

+20.04%

+18.10% (Cat Avg.)

Since Inception

+16.54%

(Cat Avg.)

Portfolio Summaryas of 31st March 2025

Equity209.4 Cr97.95%
Others4.37 Cr2.05%

Top Holdings

All Holdings

Equity

Debt & Others

NameType sortAmount sortHoldings sort
Sun Pharmaceuticals Industries LtdEquity34.67 Cr16.22%
Divi's Laboratories LtdEquity12.74 Cr5.96%
Lupin LtdEquity12.35 Cr5.78%
Suven Pharmaceuticals LtdEquity11.52 Cr5.39%
Apollo Hospitals Enterprise LtdEquity11.03 Cr5.16%
Max Healthcare Institute Ltd Ordinary SharesEquity10.83 Cr5.07%
Torrent Pharmaceuticals LtdEquity8.79 Cr4.11%
Aurobindo Pharma LtdEquity7.71 Cr3.61%
Mankind Pharma LtdEquity6.6 Cr3.09%
Alkem Laboratories LtdEquity6.08 Cr2.84%
Aster DM Healthcare Ltd Ordinary SharesEquity6.02 Cr2.81%
Abbott India LtdEquity5.19 Cr2.43%
Neuland Laboratories LimitedEquity4.87 Cr2.28%
Net Receivables / (Payables)Cash4.37 Cr2.05%
Granules India LtdEquity4.26 Cr1.99%
Dr Reddy's Laboratories LtdEquity4.08 Cr1.91%
Wockhardt LtdEquity4.05 Cr1.90%
HealthCare Global Enterprises LtdEquity3.68 Cr1.72%
Supriya Lifescience LtdEquity3.65 Cr1.71%
Fortis Healthcare LtdEquity3.34 Cr1.56%
Sumitomo Chemical India Ltd Ordinary SharesEquity3.24 Cr1.52%
FDC LtdEquity3.07 Cr1.44%
GlaxoSmithKline Pharmaceuticals LtdEquity2.97 Cr1.39%
Rainbow Childrens Medicare LtdEquity2.82 Cr1.32%
Orchid Pharma LtdEquity2.81 Cr1.32%
Caplin Point Laboratories LtdEquity2.65 Cr1.24%
J.B. Chemicals & Pharmaceuticals LtdEquity2.63 Cr1.23%
Gland Pharma LtdEquity2.62 Cr1.22%
Emcure Pharmaceuticals LtdEquity2.5 Cr1.17%
Sai Life Sciences LtdEquity2.26 Cr1.06%
Vijaya Diagnostic Centre LtdEquity2.25 Cr1.05%
Cipla LtdEquity2.22 Cr1.04%
OneSource Specialty Pharma LtdEquity2.19 Cr1.03%
Shilpa Medicare LtdEquity2.19 Cr1.02%
SRF LtdEquity2.1 Cr0.98%
UPL LtdEquity2.04 Cr0.95%
Linde India LtdEquity1.96 Cr0.92%
Sequent Scientific LtdEquity1.95 Cr0.91%
Strides Pharma Science LtdEquity1.84 Cr0.86%
Laurus Labs LtdEquity1.59 Cr0.74%

Allocation By Market Cap (Equity)

Large Cap Stocks

29.24%

Mid Cap Stocks

33.78%

Small Cap Stocks

31.63%

Other Allocation

Equity Sector

Debt & Others

SectorAmount sortHoldings sort
Healthcare195.18 Cr91.30%
Basic Materials7.25 Cr3.39%
Industrials2.1 Cr0.98%

Risk & Performance Ratios

Standard Deviation

This fund

16.41%

Cat. avg.

16.77%

Lower the better

Sharpe Ratio

This fund

0.83

Cat. avg.

0.75

Higher the better

Sortino Ratio

This fund

--

Cat. avg.

1.30

Higher the better

Fund Managers

Dhimant Shah

Dhimant Shah

Since December 2022

Rohan Korde

Rohan Korde

Since November 2021

Additional Scheme Detailsas of 31st March 2025

ISIN
INF00XX01BO9
Expense Ratio
0.47%
Exit Load
1.00%
Fund Size
₹214 Cr
Age
3 years 5 months
Lumpsum Minimum
₹5,000
Fund Status
Open Ended Investment Company
Benchmark
Nifty Healthcare TR INR

Investment ObjectiveInvestment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

iconCapital Gains Taxation:

iconDividend Taxation:

info icon

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund nameExpense RatioExit LoadFund size
1Y
Bajaj Finserv Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹307.40 Cr-
Bajaj Finserv Healthcare Fund Direct Growth

Very High Risk

0.6%1.0%₹307.40 Cr-
PGIM India Healthcare Fund Direct Growth

Very High Risk

0.7%0.0%₹104.18 Cr-
PGIM India Healthcare Fund Regular Growth

Very High Risk

2.4%0.0%₹104.18 Cr-
WhiteOak Capital Pharma and Healthcare Fund Regular Growth

Very High Risk

2.4%1.0%₹303.62 Cr26.8%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth

Very High Risk

0.6%1.0%₹303.62 Cr29.0%
DSP Nifty Healthcare ETF Regular Growth

Very High Risk

0.2%-₹9.77 Cr15.8%
Kotak Healthcare Fund Direct Growth

Very High Risk

0.8%0.0%₹411.54 Cr16.3%
Kotak Healthcare Fund Regular Growth

Very High Risk

2.4%0.0%₹411.54 Cr14.4%
HDFC Pharma and Healthcare Fund Regular Growth

Very High Risk

2.1%1.0%₹1634.08 Cr27.7%

About the AMC

ITI Mutual Fund

ITI Mutual Fund

Total AUM

₹7,941 Cr

Address

Mumbai, 400013

Other Funds by ITI Mutual Fund

Fund nameExpense RatioExit LoadFund size
1Y
ITI Focused Equity Fund Direct Growth

Very High Risk

0.7%1.0%₹478.53 Cr12.4%
ITI Liquid Fund Direct Growth

Low to Moderate Risk

0.1%0.0%₹48.22 Cr7.2%
ITI Ultra Short Duration Fund Direct Growth

Low to Moderate Risk

0.2%0.0%₹180.28 Cr7.6%
ITI Multi Cap Fund Direct Growth

Very High Risk

0.3%1.0%₹1116.36 Cr3.0%
ITI Value Fund Direct Growth

Very High Risk

0.6%1.0%₹297.69 Cr2.4%
ITI Conservative Hybrid Fund Direct Growth

Moderate Risk

0.2%0.0%₹14.80 Cr8.9%
ITI Dynamic Bond Fund Direct Growth

Moderate Risk

0.1%0.0%₹39.64 Cr11.8%
ITI Balanced Advantage Fund Direct Growth

Very High Risk

0.6%1.0%₹382.77 Cr6.8%
ITI Small Cap Fund Direct Growth

Very High Risk

0.6%1.0%₹2219.20 Cr11.1%
ITI Large Cap Fund Direct Growth

Very High Risk

0.6%1.0%₹472.57 Cr3.9%
ITI Banking & PSU Debt Fund Direct Growth

Moderate Risk

0.1%0.0%₹34.80 Cr9.2%
ITI Banking and Financial Services Fund Direct Growth

Very High Risk

0.6%1.0%₹287.76 Cr17.0%
ITI Arbitrage Fund Direct Growth

Low Risk

0.2%0.0%₹47.67 Cr7.8%
ITI Overnight Fund Direct Growth

Low Risk

0.1%0.0%₹21.96 Cr6.4%
ITI Mid Cap Fund Direct Growth

Very High Risk

0.2%1.0%₹1091.64 Cr7.1%
ITI Long Term Equity Fund Direct Growth

Very High Risk

0.6%0.0%₹377.68 Cr7.7%
ITI Pharma and Healthcare Fund Direct Growth

Very High Risk

0.5%1.0%₹213.77 Cr18.5%
ITI Flexi Cap Fund Direct Growth

Very High Risk

0.2%1.0%₹1031.77 Cr8.2%

Still got questions?
We're here to help.

The NAV of ITI Pharma and Healthcare Fund Direct Growth, as of 17-Apr-2025, is ₹16.92.
The fund has generated 18.55% over the last 1 year and 20.04% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.
The fund's allocation of assets is distributed as 97.95% in equities, 0.00% in bonds, and 2.05% in cash and cash equivalents.
The fund managers responsible for ITI Pharma and Healthcare Fund Direct Growth are:-
  1. Dhimant Shah
  2. Rohan Korde
close

Get your portfolio reviewed by experts

qr

Track all your investments in one place

Download Wealth Monitor App

cross
wm logo

Track and monitor all
your investments